USA Phase II Clinical Trial Begins for PluroGen’s PluroGel® PN

Posted on February 19, 2015 by - Uncategorized

Download PDF

2495 General Armistead Avenue ● Norristown, Pennsylvania 19403 ● USA ● Tel: +1 (610) 539-3670 ● Fax: +1 (610) 539-3831

(Norristown, Pennsylvania, USA, 21 August 2013) – PluroGen Therapeutics, Inc., a leader in advanced wound care solutions, announced today that its PluroGel® PN topical antibiotic, utilizing a unique combination of antibiotics in its differentiated and patent protected PluroGel®, has started its USA Phase II clinical trial for infected diabetic foot ulcers. Currently, PluroGen’s research shows that there is no topical antibiotic approved by FDA for the treatment of infections of diabetic foot ulcers. Diabetes is a disease estimated to afflict approximately 28 million people in the US alone. Many diabetics have the additional problem of a chronic condition known as diabetic foot ulcer and patients with diabetic foot ulcer experience a high rate of infection known as diabetic foot infection. Currently, it is thought that approximately 3 million patients per year are treated for diabetic foot infection in the USA. The worldwide market for diabetic foot infection is estimated at approximately $1.5 billion in 2011 with the affliction and market expected to continue growth, driven by the aging population, growing obesity and the increasing diagnosis of diabetes.

“We have achieved another major milestone this summer.” said Neal Koller, President and CEO of PluroGen.

“Beginning the Phase II clinical trial builds on the success of the approximately 12,000 patients treated with the early version of PluroGel® PN at the University of Virginia which supported FDA’s agreement to fast-track our clinical trial plan. The Phase II clinical trial is a big step towards entrance into the USA market, to improve care for patients and to increase shareholder value.”

For Immediate Release
21 August 2013
Contact: Tricia Thompson
Business Development
+1 (610) 539-3670

PluroGen Patent Application Receives Allowance of Claims Notice

Posted on February 19, 2015 by - Uncategorized

Download PDF

2495 General Armistead Avenue ● Norristown, Pennsylvania 19403 ● USA ● Tel: +1 (610) 539-3670 ● Fax: +1 (610) 539-3831

(Norristown, Pennsylvania, USA, 15 August 2013) – PluroGen Therapeutics, Inc., a leader in advanced wound care solutions, announced today that its Natural Gel Technology patent application received an Allowance of Claims Notice from the United States Patent and Trademark Office (USPTO).

Patent protection for PluroGel® Products can be extended well into 2030 when the patent issues for this new technology. The Natural Gel Technology provides clinically important new features for PluroGel® Products.

“The patient success our PluroGel® Products are achieving now is well beyond competition. The new features that the Natural Gel Technology provides to PluroGel® Products will elevate them to yet another level in performance, providing more value for doctors, clinicians and patients” commented Neal Koller, President and CEO of PluroGen. “Allowance of these patent claims by the USPTO is an important milestone for product protection and enhancement of shareholder value”.

For Immediate Release
15 August 2013
Contact: Tricia Thompson
Business Development
+1 (610) 539-3670

Ground-breaking PluroGel® Clinical Results Symposium Conducted During European Wound Management Association (EWMA) Conference 2013 15 to 17 May, Copenhagen, Denmark

Posted on February 19, 2015 by - Uncategorized

Download PDF

2495 General Armistead Avenue ● Norristown, Pennsylvania 19403 ● USA ● Tel: +1 (610) 539-3670 ● Fax: +1 (610) 539-3831 www.plurogen.com

(Norristown, Pennsylvania, USA, 01 July 2013) – PluroGen Therapeutics, Inc., a leader in advanced wound care solutions, announced today that a ground-breaking Symposium on its PluroGel® Products was conducted during the 2013 European Wound Management Association (EWMA) Conference in Copenhagen, Denmark, 15-17 May.

The 2013 Symposium included presentations covering clinical successes and cost savings from 10 centers in 7 countries reporting results from a population of over 1,200 patients. The 2013 PluroGel® Symposium was well attended, the symposium room being filled at capacity with over 70 invited doctors and nurses in the audience to hear and ask questions on the clinical advantages and cost savings achieved by the use of PluroGel® Products. The 2013 Symposium significantly expanded on the patient successes and unique PluroGel® benefits reported at the 2012 PluroGel® Products Symposium. Presentations from the 2013 Symposium can be viewed at our website, www.plurogen.com, with a password supplied by PluroGen. To obtain a password, please contact PluroGen at info@plurogen.com.

“We continued to tell our story about how our new PluroGel® surfactant products are helping physicians make great strides in their day to day wound care challenges” commented Neal Koller, President and CEO of PluroGen. “The results are consistent and exemplify how PluroGel® Products can create much-improved opportunities for wound care management. It’s wonderful to be able to have such a positive impact for doctors, nurses and, most importantly, patients.”

For Immediate Release
01 July 2013
Contact: Tricia Thompson
Business Development
+1 (610) 539-3670

PluroGen Therapeutics, Inc. To Attend the European Wound Management Association (EWMA) Conference 2013, 15 to 17 May in Copenhagen, Denmark

Posted on February 19, 2015 by - Uncategorized

Download PDF

2495 General Armistead Avenue ● Norristown, Pennsylvania 19403 ● USA ● Tel: +1 (610) 539-3670 ● Fax: +1 (610) 539-3831

FOR IMMEDIATE RELEASE

Norristown, PA, 12 April, 2013

PluroGen Therapeutics, Inc, an emerging leader in advanced wound care solutions, announced today that it will be attending the European Wound Management Association (EWMA) Conference to be held at the Bella Center in Copenhagen, Denmark, 15-17 May, 2013. PluroGen will be discussing and demonstrating its PluroGel® line of wound care products. Neal Koller, President and CEO of PluroGen and Kati Weiss, European Manager will be available throughout the conference for one-onone meetings at the PluroGen Booth #C2-029, located in the Bella Conference Center. To set up a meeting during the show with a PluroGen representative, please email europe@plurogen.com.

PluroGen has developed a portfolio of 3 synergistic and complementary patented technologies that are sharply focused to products for the burn, wound and skin care markets. PluroGel PSSD, one of PluroGen’s line of patented surfactant burn and wound products is being used in burn and wound centers across Europe. “Our team is very excited about returning to the EWMA Conference. We had such tremendous response last year in Vienna that we wanted to continue our discussions and share PluroGel’s wound care success stories with conference attendees.” said Neal Koller, President and CEO of PluroGen. “We want to continue to tell our story about how our new PluroGel surfactant products can help physicians make great strides in their day to day wound care challenges.”

About European Wound Management Association

The European Wound Management Association (EWMA) was founded in 1991, and the association works to promote the advancement of education and research into native epidemiology, pathology, diagnosis, prevention and management of wounds of all aetiologies. Over 2000 experts, practitioners and company representatives working with wound healing and wound management will be in attendance. More than 2900 participants and exhibitors joined the EWMA 2012 conference in Vienna. We look forward to seeing you in 2013 in Copenhagen. Additional information on the conference can be found at http://www.ewma2013.org.

Safe Harbor Statement:

The statements in the press release that relate to PluroGen’s (the company) expectations with regard to the future impact on the company’s results from new products in development and any other statements not constituting historical facts are “forward-looking statements,” within the meaning of and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the company’s actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company’s operations, current and future performance and financial condition. These items involve risks, contingencies and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks, contingencies and uncertainties which could cause the company’s actual operating results, performance, business plans or prospects to differ materially from those expressed in, or implied by these statements. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.

LIFE SCIENCE INDUSTRY EXECUTIVE ELECTED TO PLUROGEN BOARD OF DIRECTORS

Posted on February 19, 2015 by - Uncategorized

Download PDF

FOR IMMEDIATE RELEASE Contact: Neal G. Koller
President & CEO
20 February 2011 Board of Directors
+1 (443) 994-0101

(Charlottesville, VA, 20 February 2011) – PluroGen Therapeutics, Inc. is pleased to announce that Daniel M. Brody has been elected to the PluroGen Board of Directors.

Mr. Brody joins PluroGen with a distinguished and successful career in life sciences, entrepreneurial business growth and board management. He is the Founder and CEO of Health Data Services, Inc., which has grown to become one of the country’s premier medical practice management software and services companies and developer of MedLedger, an ONC-ATCB Certified Complete EHR.

Mr. Brody served on the Board of Directors and Executive Committee of Insmed, Inc., (NASDAQ: INSMD). He has also served on the Board of the Virginia Department of Medical Assistance (Virginia Medicaid) (1994-2002) and was its Chairman (1996-2000), the University of Virginia 2020 Strategic Planning Committee, the Learning Center of Virginia, the Charlottesville-Albemarle Community Foundation, and Congregation Beth Israel.

Mr. Brody is the Managing Partner of Greenwood Partners and an Adjunct Professor at the University of Virginia. Mr. Brody serves on the boards of Prolifiq Software, the Hillel Foundation at the University of Virginia, and the Foundation of Hillel International.

Mr Brody earned a B.A. in Economics from the University of Virginia and an MBA from New York University – Leonard N. Stern School of Business.

Neal G. Koller, President & CEO of PluroGen, commenting on Mr. Brody joining the PluroGen Board of Directors said “Mr. Brody’s entrepreneurial success in building Health Data Systems will bring a unique and valued set of skills to the PluroGen Board. We are honored to have him accept our offer and look forward to working with him.”

Information included on PluroGen Therapeutics, Inc website is not incorporated herein by reference or otherwise.

PluroGen Therapeutics, Inc.
503 Broadleaf Way
Charlottesville, VA 22911
Tel: +1 (434) 563-4321
Fax: +1 (434) 563-4322
www.plurogen.com

PluroGen Receives & Ships 1st Austrian Order for PluroGel® with Silver Sulphadiazine

Posted on February 19, 2015 by - Uncategorized

Download PDF

FOR IMMEDIATE RELEASE Contact: Neal G. Koller
President & CEO
Board of Directors
February 18, 2011 +1 (443) 994-0101

(Charlottesville, VA, 18 February 2011) – PluroGen Therapeutics, Inc. today announced that it has received and shipped its first order to its Austrian distribution partner for PluroGel® with Silver Sulphadiazine.

Neal G. Koller, President & CEO of PluroGen, commenting on the first Austrian order said “Europe is estimated at a $2.6 billion market opportunity for PluroGen, with Austria at $59.5 million. Austria is a significant revenue and profit opportunity for the Company. Our new Austrian distribution partner will provide a solid sales, marketing and distribution base for PluroGel® with Silver Sulphadiazine. They are an established company with long-term and excellent relationships in the Austrian physician, hospital, nursing home and pharmacy markets. We look forward to great success in Austria.”

Information included on PluroGen Therapeutics, Inc. website is not incorporated herein by reference or otherwise.

PluroGen Therapeutics, Inc.
2495 General Armistead Avenue
Norristwon, Pennsylvania 19403
Tel: +1 (434) 563-4321
Fax: +1 (434) 563-4322
www.plurogen.com

PluroGen Expands into its Own 21,000 sq. ft. Multi-Purpose Facility

Posted on February 19, 2015 by - Uncategorized

Download PDF

FOR IMMEDIATE RELEASE Contact: Neal G. Koller
President & CEO
Board of Directors
January 20, 2011 +1 (443) 994-0101

(Norristown, PA, 20 January 2011) – PluroGen Therapeutics, Inc. today announced that it has expanded its operations moving into its own 21,000 sq. ft. facility in Norristown, PA. PluroGen’s new facility houses a multipleroom ISO 6 clean-room for product manufactuing, laboratory space, climate-controlled warehousing and offices.

Neal G. Koller, President & CEO of PluroGen, remarks, “Our new facility provides PluroGen the ability to make and deliver our ground-breaking products:

  • Single-Antibiotic PluroGel® SSD just launched for our European customers and their patients
  • Triple-Antibiotic PluroGel® PNN for our $8.6M contract with US DoD to obtain FDA approval)
  • And PluroGel® only concentrate for our skin & wound cleansing wet wipes partner in Europe”

“The new facility provides us with the space and capacity to hire the addtional personnel and place the needed production equipment to support our US Depatment of Defense award and our worldwide demand for PluroGel® products. PluroGen now has the manufacturing and operations platform needed to support our sales growth for a number years into the future. This is a very important and milestone step forward for the Compnay.”

Information included on PluroGen Therapeutics, Inc. website is not incorporated herein by reference or otherwise.

PluroGen Therapeutics, Inc.
2495 General Armistead Avenue
Norristwon, Pennsylvania 19403
Tel: +1 (434) 563-4321
Fax: +1 (434) 563-4322
www.plurogen.com

PluroGen Marks Milestone: Enters Europe with Flagship PluroGel® with Silver Sulphadiazine Makes 1st Shipment to Switzerland

Posted on February 19, 2015 by - Uncategorized

Download PDF

FOR IMMEDIATE RELEASE Contact: Neal G. Koller
President & CEO
Board of Directors
September 13, 2010 +1 (443) 994-0101

(Charlottesville, VA, 13 September 2010) – PluroGen Therapeutics, Inc. today announced that it has entered the European market for its flagship PluroGel® with Silver Sulphadiazine, making the 1st shipment to Switzerland to its Swiss distribution partner.

Commenting on the first European shipment of PluroGel® with Silver Sulphadiazine, Neal G. Koller, PluroGen President & CEO, said “Entering Europe opens an estimated $2.6 billion market for PluroGen. Switzerland alone is estimated at $53.2 million. This shipment marks achievement of the key milestone in a company’s development, transition for PluroGen to a fully commercial company. Our new Swiss distribution partner is well established in the market with terrific relationships across all market segments and will be a great driver in our market penetration.”

Information included on PluroGen Therapeutics, Inc. website is not incorporated herein by reference or otherwise.

PluroGen Therapeutics, Inc.
503 Broadleaf Way
Chrlottesville, Virginia 22911
Tel: +1 (434) 563-4321
Fax: +1 (434) 463-4322
www.plurogen.com

PLUROGEN SIGNS $ 8.6 MILLION CONTRACT WITH U.S. DEPARTMENT OF DEFENSE – PLUROGEN’S PLUROGEL® PNN CHOSEN FOR LIMB SALVAGE & REGENERATIVE MEDICINE INITIATIVE

Posted on February 19, 2015 by - Uncategorized

Download PDF

(Charlottesville, VA, 1 September 2010) – PluroGen Therapeutics, Inc. (PluroGen) is pleased to announce the United States Department of Defense (DoD), via the Department of Interior’s National Business Center (DoI-NBC), has selected PluroGel® PNN Topical Antimicrobial, a triple antibacterial and antifungal, as part of the Limb Salvage and Regenerative Medicine Initiative. This Initiative is a Department of Defense-wide collaborative effort, funded partially by the Joint IED Defeat Organization to accelerate medical technology for the treatment of blast-related injuries. The contract with PluroGen is valued at $8,600,000 and funds the regulatory approval process and the manufacturing scale-up of PluroGel® PNN Topical Antimicrobial, which is targeted to severe burns and wounds.

The Limb Salvage and Regenerative Medicine Initiative is managed by the Office of Technology Transition, within the Directorate for Defense Research and Engineering (DDR&E). The Limb Salvage and Regenerative Medicine Initiative is a pilot program to shepherd needed and beneficial advanced medical technologies and products through the transition process for DoD, and civilian, use. PluroGel® PNN has been demonstrated at the University of Virginia Health System to be an effective topical antimicrobial technology that could benefit our troops, especially those on the front lines. The DoD is partnered with PluroGen to be able to help this technology transition into everyday use for our burn and wound patients.

Commenting on this significant achievement for PluroGen, Neal G. Koller, President & CEO of PluroGen, said “Signing this contract with U.S. DoD is a terrific opportunity for PluroGen to contribute in a most significant and important way to our wounded Service Members by providing our soldiers with PluroGel® PNN. PluroGel® PNN has been in use for 15 years on over 9,500 severe burn and chronic wound patients at the University of Virginia. PluroGel® PNN, if approved by the FDA, will give the Department of Defense another topical antimicrobial therapy capability for battlefield injuries. U.S. DoD’s $8.6 million funding and support of our PluroGel® technology will assure our military and all severe burn and wound patients worldwide of having access to the advantages of our unique PluroGel® PNN.”

Information included on PluroGen Therapeutics, Inc. website is not incorporated herein by reference or otherwise.

PluroGen Therapeutics, Inc.
503 Broadleaf Way
Charlottesville, VA 22911
Tel: +1 434 563 4321
Fax: +1 434 563 4322
www.PluroGen.com

Dan Conley
Investor Relations
OnCallCFO@gmail.com
+ 1 908 917 3537
Contacts: Neal G. Koller
President & CEO
NKoller@PluroGen.com
+ 1 443 994 0101

PHARMACEUTICAL INDUSTRY MARKETING EXECUTIVE & VAAN PROFESSIONAL ANGEL GROUP MEMBER ELECTED TO PLUROGEN BOARD OF DIRECTORS

Posted on February 19, 2015 by - Uncategorized

Download PDF

FOR IMMEDIATE RELEASE Contact: Neal G. Koller
President & CEO
30 July 2010 Board of Directors
+1 (443) 994-0101

(Charlottesville, VA, 30 July 2010) – PluroGen Therapeutics, Inc. is pleased to announce that Wendy Yarno has been elected to the PluroGen Board of Directors.

Ms. Yarno joins the PluroGen board continuing her distinguished career in life sciences. She has over 26 years experience in the pharmaceutical industry with Johnson & Johnson and Merck & Co., Inc. where she has held a number of executive positions in the marketing, sales, human resources and policy areas. Ms. Yarno most recently was Executive Vice President and Chief Marketing Officer at Merck & Co., Inc., and retired from Merck in 2008. She is currently on the Board of Directors of St. Jude Medical (NYSE: STJ) a medical device company headquartered in Minneapolis, MN, and ADial Pharmaceuticals in Charlottesville, VA. Additionally, Ms. Yarno is on the Board of Advisors of HemoShear, LLC., OpenQ, LLC. and the University of Virginia Patent Foundation. She earned an MBA from Temple University in Philadelphia, PA, and a B.S. in Marketing from Portland State University in Portland, OR.

Commenting on Ms Yarno’s joining the Plurogen Board of Directors, Neal G. Koller, President & CEO of PluroGen, said “PluroGen is honored and very pleased to have Ms. Yarno join our Board of Directors. Her deep and broad experience, relationships and understanding of the life science industry will add considerably to PluroGen’s expertise and capabilities.”

About PluroGen Therapeutics, Inc.

PluroGen is a burn, wound, and skin care company commercializing its multiple patent-protected technology platforms. The Company’s primary platform is its core PluroGel® technology which provides paradigm-shifting, superior and differentiated physical, bio-impact, and multi-function products. PluroGel® is University developed and is in routine use at the University, having shown superior results on more than 10,000 patients in two different patient populations – severe burns and wounds. PluroGen’s three technology platforms are configured to deliver a variety of medicinal and beneficial compounds covering the six key areas of treatment in tissue management and healing: 1. Cleansing; 2. Anti-Infection; 3. Reduced Pain; 4. Anti- Inflammation; 5. Tissue salvage; 6. Tissue regeneration.

PluroGen has a strong new product pipeline including PluroGel® Barrier Gels and Dressings, PluroGel® branded topical antimicrobial prescription products and PluroGel® co-branded products with select commercial partners.

PluroGen’s senior management, operations team, boards and principal investigators are all recognized global commercial and clinical leaders in PluroGen’s target markets of burn and wound care.

For more information about PluroGen Therapeutics, Inc., visit the Company’s web site at www.plurogen.com.

Statements included in this press release that are not historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. The Company cautions readers that forward-looking statements are subject to certain risks and uncertainties, which could cause actual results to differ materially and which are identified from time to time in the Company’s reports filed with the U.S. Securities and Exchange Commission. PluroGen Therapeutics, Inc. claims the protection of the Safe Harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.

Information included on PluroGen Therapeutics, Inc website is not incorporated herein by reference or otherwise.

PluroGen Therapeutics, Inc.
503 Broadleaf Way
Charlottesville, VA 22911
Tel: +1 (434) 563-4321
Fax: +1 (434) 563-4322
www.plurogen.com